Click the thumbnails below to view the Life Sciences IP Review magazines.
 |
Spring is here and the UK government is marking it by airing its Genetic Technology (Precision Breeding) Bill, promising to breathe new life into an area apparently suffocated by EU red tape. LSIPR new recruit Sarah Speight asks lawyers working in the space what this means for patent protection before digging deeper into the issues around plant breeders’ rights and the hot potato that is genetically modified organisms (page 6). And this LSIPR brings you yet more in-depth articles full of future promise, looking at everything from start-ups to fungi. |
 |
This issue examines big pharma's five-step plan, its alternative to the controversial IP waiver. Elsewhere, it analyses the impact of China's latest IP laws, the potentially chilling effect of the ‘essentially derived varieties’ concept protecting plant varieties, and experimental use exemptions in the UK, plus more. |
 |
The Spring/Summer edition of LSIPR includes warnings about patent eligibility for digital healthcare. Focusing on two cases, one involving the growing areas of bioinformatics, our authors explain why having a novel and useful invention may not be enough. We also look into the Federal Circuit's trend of undermining certain antibody claims, the European Patent Office's new examination guidelines, and where life sciences startups are choosing to file patents. Meanwhile, heard the one about the Wuhan lab and remdesivir? A curious situation involving COVID-19, Gilead, and China's updated patent laws is explored, offering more questions than answers. Enjoy the issue! |
 |
This issue covers a wide variety of hot topics in life sciences IP. Alongside COVID-19 issues (with an argument against compulsory licensing by Robin Jacob being particularly of note), this edition visits the doctrine of equivalents in assessing medtech patents, and a double-bill of European Patent Office-focused articles, looking at plausibility and reasonable scope for antibody-related inventions. Other topics include supplementary protection certificates, cannabis patents, and the important issue of mental health treatments in precision medicine. |
 |
This issue focuses largely on COVID 19. Stories of vaccine production, disputes over Gilead’s remdesivir, and the price-gouging of face masks, have evolved as the pandemic took hold. Other pandemic-related topics are examined in depth by a selection of top industry authors, topics such as patent procurement and licensing, the UK’s attempt to protect ventilator manufacturers from IP lawsuits, and how nations could fall out over the sharing of vaccines. |
 |
|
 |
|
 |
|
 |
|
 |
50 Key influencers in the life sciences 2018
|
 |
|
 |
Life Sciences IP Review Conference Special 2017
|
 |
Life Sciences IP Review Top 50 2017
|
 |
|
 |
Life Sciences IP Review Top 50 2016
|
 |
Life Sciences IP Review Conference Special 2016 Highlights: |
 |
Life Sciences IP Review Autumn Special 2015 Highlights: |
 |
Life Sciences IP Review Conference Special 2015 Highlights: |
 |
Find all the monthly editions of the digital magazine here. |
 |
Life Sciences IP Review Quarterly 2.2 Highlights: |
 |
Life Sciences IP Review Quarterly 2.1 Highlights: |
 |
Life Sciences IP Review Quarterly 1.4 Highlights: |
 |
Life Sciences IP Review Quarterly 1.3 Highlights: |
 |
Life Sciences IP Review Quarterly 1.2 Highlights: |
 |
Life Sciences IP Review Quarterly 1.1
|
 |
Life Sciences IP Review Annual 2013 Highlights:
|
 |
Life Sciences IP Review Annual 2012 Highlights:
|
 |
Life Sciences IP Review Annual 2011 Highlights:
|
 |
Life Sciences IP Review Annual 2010 Highlights:
|
 |
Life Sciences IP Review Annual 2009 Highlights:
|
 |
Life Sciences IP Review Annual 2008 Highlights:
|
